Melanoma.
Identifieur interne : 002B49 ( Main/Exploration ); précédent : 002B48; suivant : 002B50Melanoma.
Auteurs : Dirk Schadendorf [Allemagne] ; David E. Fisher [États-Unis] ; Claus Garbe [Allemagne] ; Jeffrey E. Gershenwald [États-Unis] ; Jean-Jacques Grob [France] ; Allan Halpern [États-Unis] ; Meenhard Herlyn [États-Unis] ; Michael A. Marchetti [États-Unis] ; Grant Mcarthur [Australie] ; Antoni Ribas [États-Unis] ; Alexander Roesch [Allemagne] ; Axel Hauschild [Allemagne]Source :
- Nature reviews. Disease primers [ 2056-676X ] ; 2015.
Abstract
Melanoma is a common cancer in the Western world with an increasing incidence. Sun exposure is still considered to be the major risk factor for melanoma. The prognosis of patients with malignant (advanced-stage) melanoma differs widely between countries, but public campaigns advocating early detection have led to significant reductions in mortality rates. As well as sun exposure, distinct genetic alterations have been identified as associated with melanoma. For example, families with melanoma who have germline mutations in CDKN2A are well known, whereas the vast majority of sporadic melanomas have mutations in the mitogen-activated protein kinase cascade, which is the pathway with the highest oncogenic and therapeutic relevance for this disease. BRAF and NRAS mutations are typically found in cutaneous melanomas, whereas KIT mutations are predominantly observed in mucosal and acral melanomas. GNAQ and GNA11 mutations prevail in uveal melanomas. Additionally, the PI3K-AKT-PTEN pathway and the immune checkpoint pathways are important. The finding that programmed cell death protein 1 ligand 1 (PDL1) and PDL2 are expressed by melanoma cells, T cells, B cells and natural killer cells led to the recent development of programmed cell death protein 1 (PD1)-specific antibodies (for example, nivolumab and pembrolizumab). Alongside other new drugs - namely, BRAF inhibitors (vemurafenib and dabrafenib) and MEK inhibitors (trametinib and cobimetinib) - these agents are very promising and have been shown to significantly improve prognosis for patients with advanced-stage metastatic disease. Early signs are apparent that these new treatment modalities are also improving long-term clinical benefit and the quality of life of patients. This Primer summarizes the current understanding of melanoma, from mechanistic insights to clinical progress. For an illustrated summary of this Primer, visit: http://go.nature.com/vX2N9s.
DOI: 10.1038/nrdp.2015.3
PubMed: 27188223
Affiliations:
- Allemagne, Australie, France, États-Unis
- Bade-Wurtemberg, Californie, District de Karlsruhe, Massachusetts, Pennsylvanie, Provence-Alpes-Côte d'Azur, Schleswig-Holstein, Texas, État de New York
- Heidelberg, Kiel, Marseille
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002E96
- to stream PubMed, to step Curation: 002E18
- to stream PubMed, to step Checkpoint: 002E18
- to stream Ncbi, to step Merge: 003553
- to stream Ncbi, to step Curation: 003553
- to stream Ncbi, to step Checkpoint: 003553
- to stream Main, to step Merge: 002B49
- to stream Main, to step Curation: 002B49
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Melanoma.</title>
<author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Duisburg-Essen, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University Duisburg-Essen, University Hospital Essen, Hufelandstrasse 55, 45147 Essen</wicri:regionArea>
<wicri:noRegion>45147 Essen</wicri:noRegion>
<wicri:noRegion>45147 Essen</wicri:noRegion>
<wicri:noRegion>45147 Essen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fisher, David E" sort="Fisher, David E" uniqKey="Fisher D" first="David E" last="Fisher">David E. Fisher</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name>
<affiliation wicri:level="3"><nlm:affiliation>German Cancer Consortium (DKTK), Heidelberg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>German Cancer Consortium (DKTK), Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gershenwald, Jeffrey E" sort="Gershenwald, Jeffrey E" uniqKey="Gershenwald J" first="Jeffrey E" last="Gershenwald">Jeffrey E. Gershenwald</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology and Skin Cancers, APHM Timone Hospital Aix-Marseille University, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology and Skin Cancers, APHM Timone Hospital Aix-Marseille University, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Halpern, Allan" sort="Halpern, Allan" uniqKey="Halpern A" first="Allan" last="Halpern">Allan Halpern</name>
<affiliation wicri:level="2"><nlm:affiliation>Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Herlyn, Meenhard" sort="Herlyn, Meenhard" uniqKey="Herlyn M" first="Meenhard" last="Herlyn">Meenhard Herlyn</name>
<affiliation wicri:level="2"><nlm:affiliation>Melanoma Research Center, Wistar Institute, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Melanoma Research Center, Wistar Institute, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marchetti, Michael A" sort="Marchetti, Michael A" uniqKey="Marchetti M" first="Michael A" last="Marchetti">Michael A. Marchetti</name>
<affiliation wicri:level="2"><nlm:affiliation>Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcarthur, Grant" sort="Mcarthur, Grant" uniqKey="Mcarthur G" first="Grant" last="Mcarthur">Grant Mcarthur</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Medicine, Surgery, and Medical and Molecular Pharmacology, University of California Los Angeles, Los Angeles, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Medicine, Surgery, and Medical and Molecular Pharmacology, University of California Los Angeles, Los Angeles, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roesch, Alexander" sort="Roesch, Alexander" uniqKey="Roesch A" first="Alexander" last="Roesch">Alexander Roesch</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Duisburg-Essen, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University Duisburg-Essen, University Hospital Essen, Hufelandstrasse 55, 45147 Essen</wicri:regionArea>
<wicri:noRegion>45147 Essen</wicri:noRegion>
<wicri:noRegion>45147 Essen</wicri:noRegion>
<wicri:noRegion>45147 Essen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Kiel, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Kiel</wicri:regionArea>
<placeName><region type="land" nuts="2">Schleswig-Holstein</region>
<settlement type="city">Kiel</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:27188223</idno>
<idno type="pmid">27188223</idno>
<idno type="doi">10.1038/nrdp.2015.3</idno>
<idno type="wicri:Area/PubMed/Corpus">002E96</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E96</idno>
<idno type="wicri:Area/PubMed/Curation">002E18</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002E18</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002E18</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002E18</idno>
<idno type="wicri:Area/Ncbi/Merge">003553</idno>
<idno type="wicri:Area/Ncbi/Curation">003553</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003553</idno>
<idno type="wicri:Area/Main/Merge">002B49</idno>
<idno type="wicri:Area/Main/Curation">002B49</idno>
<idno type="wicri:Area/Main/Exploration">002B49</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Melanoma.</title>
<author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Duisburg-Essen, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University Duisburg-Essen, University Hospital Essen, Hufelandstrasse 55, 45147 Essen</wicri:regionArea>
<wicri:noRegion>45147 Essen</wicri:noRegion>
<wicri:noRegion>45147 Essen</wicri:noRegion>
<wicri:noRegion>45147 Essen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fisher, David E" sort="Fisher, David E" uniqKey="Fisher D" first="David E" last="Fisher">David E. Fisher</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name>
<affiliation wicri:level="3"><nlm:affiliation>German Cancer Consortium (DKTK), Heidelberg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>German Cancer Consortium (DKTK), Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gershenwald, Jeffrey E" sort="Gershenwald, Jeffrey E" uniqKey="Gershenwald J" first="Jeffrey E" last="Gershenwald">Jeffrey E. Gershenwald</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology and Skin Cancers, APHM Timone Hospital Aix-Marseille University, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology and Skin Cancers, APHM Timone Hospital Aix-Marseille University, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Halpern, Allan" sort="Halpern, Allan" uniqKey="Halpern A" first="Allan" last="Halpern">Allan Halpern</name>
<affiliation wicri:level="2"><nlm:affiliation>Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Herlyn, Meenhard" sort="Herlyn, Meenhard" uniqKey="Herlyn M" first="Meenhard" last="Herlyn">Meenhard Herlyn</name>
<affiliation wicri:level="2"><nlm:affiliation>Melanoma Research Center, Wistar Institute, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Melanoma Research Center, Wistar Institute, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marchetti, Michael A" sort="Marchetti, Michael A" uniqKey="Marchetti M" first="Michael A" last="Marchetti">Michael A. Marchetti</name>
<affiliation wicri:level="2"><nlm:affiliation>Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcarthur, Grant" sort="Mcarthur, Grant" uniqKey="Mcarthur G" first="Grant" last="Mcarthur">Grant Mcarthur</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Medicine, Surgery, and Medical and Molecular Pharmacology, University of California Los Angeles, Los Angeles, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Medicine, Surgery, and Medical and Molecular Pharmacology, University of California Los Angeles, Los Angeles, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roesch, Alexander" sort="Roesch, Alexander" uniqKey="Roesch A" first="Alexander" last="Roesch">Alexander Roesch</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Duisburg-Essen, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University Duisburg-Essen, University Hospital Essen, Hufelandstrasse 55, 45147 Essen</wicri:regionArea>
<wicri:noRegion>45147 Essen</wicri:noRegion>
<wicri:noRegion>45147 Essen</wicri:noRegion>
<wicri:noRegion>45147 Essen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Kiel, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Kiel</wicri:regionArea>
<placeName><region type="land" nuts="2">Schleswig-Holstein</region>
<settlement type="city">Kiel</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature reviews. Disease primers</title>
<idno type="eISSN">2056-676X</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Melanoma is a common cancer in the Western world with an increasing incidence. Sun exposure is still considered to be the major risk factor for melanoma. The prognosis of patients with malignant (advanced-stage) melanoma differs widely between countries, but public campaigns advocating early detection have led to significant reductions in mortality rates. As well as sun exposure, distinct genetic alterations have been identified as associated with melanoma. For example, families with melanoma who have germline mutations in CDKN2A are well known, whereas the vast majority of sporadic melanomas have mutations in the mitogen-activated protein kinase cascade, which is the pathway with the highest oncogenic and therapeutic relevance for this disease. BRAF and NRAS mutations are typically found in cutaneous melanomas, whereas KIT mutations are predominantly observed in mucosal and acral melanomas. GNAQ and GNA11 mutations prevail in uveal melanomas. Additionally, the PI3K-AKT-PTEN pathway and the immune checkpoint pathways are important. The finding that programmed cell death protein 1 ligand 1 (PDL1) and PDL2 are expressed by melanoma cells, T cells, B cells and natural killer cells led to the recent development of programmed cell death protein 1 (PD1)-specific antibodies (for example, nivolumab and pembrolizumab). Alongside other new drugs - namely, BRAF inhibitors (vemurafenib and dabrafenib) and MEK inhibitors (trametinib and cobimetinib) - these agents are very promising and have been shown to significantly improve prognosis for patients with advanced-stage metastatic disease. Early signs are apparent that these new treatment modalities are also improving long-term clinical benefit and the quality of life of patients. This Primer summarizes the current understanding of melanoma, from mechanistic insights to clinical progress. For an illustrated summary of this Primer, visit: http://go.nature.com/vX2N9s.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>Californie</li>
<li>District de Karlsruhe</li>
<li>Massachusetts</li>
<li>Pennsylvanie</li>
<li>Provence-Alpes-Côte d'Azur</li>
<li>Schleswig-Holstein</li>
<li>Texas</li>
<li>État de New York</li>
</region>
<settlement><li>Heidelberg</li>
<li>Kiel</li>
<li>Marseille</li>
</settlement>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name>
</noRegion>
<name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name>
<name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name>
<name sortKey="Roesch, Alexander" sort="Roesch, Alexander" uniqKey="Roesch A" first="Alexander" last="Roesch">Alexander Roesch</name>
</country>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Fisher, David E" sort="Fisher, David E" uniqKey="Fisher D" first="David E" last="Fisher">David E. Fisher</name>
</region>
<name sortKey="Gershenwald, Jeffrey E" sort="Gershenwald, Jeffrey E" uniqKey="Gershenwald J" first="Jeffrey E" last="Gershenwald">Jeffrey E. Gershenwald</name>
<name sortKey="Halpern, Allan" sort="Halpern, Allan" uniqKey="Halpern A" first="Allan" last="Halpern">Allan Halpern</name>
<name sortKey="Herlyn, Meenhard" sort="Herlyn, Meenhard" uniqKey="Herlyn M" first="Meenhard" last="Herlyn">Meenhard Herlyn</name>
<name sortKey="Marchetti, Michael A" sort="Marchetti, Michael A" uniqKey="Marchetti M" first="Michael A" last="Marchetti">Michael A. Marchetti</name>
<name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name>
</country>
<country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name>
</region>
</country>
<country name="Australie"><noRegion><name sortKey="Mcarthur, Grant" sort="Mcarthur, Grant" uniqKey="Mcarthur G" first="Grant" last="Mcarthur">Grant Mcarthur</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B49 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B49 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:27188223 |texte= Melanoma. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27188223" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |